

## Supplementary Table 1

| Clinical characteristics   | All patients (n=100) |
|--|----------------------|
| <b>Age</b>   |                      |
| Median - years   | 63                   |
| Range - years  | 37 to 88             |
| <b>Sex – n</b>   |                      |
| Female   | 38                   |
| Male   | 62                   |
| <b>Site of disease for molecular analysis on FFPE – n</b>                    |                      |
| Primary tumor  | 62                   |
| Metastatic site - Liver  | 31                   |
| Metastatic site - Lung   | 1                    |
| Metastatic site - Nodes  | 2                    |
| Metastatic site - Peritoneum   | 3                    |
| Metastatic site - Bone   | 1                    |
| <b>Gene mutation in FFPE – n</b>   |                      |
| KRAS exon 2  | 48                   |
| KRAS exon 3  | 1                    |
| KRAS exon 4  | 2                    |
| BRAF V600E   | 8                    |
| NRAS exon 2  | 2                    |
| NRAS exon 3  | 3                    |
| <b>Intact primary at the moment of liquid biopsy – n</b>                     |                      |
| YES  | 48                   |
| NO   | 49                   |
| <b>Site of disease at the moment of liquid biopsy – n</b>                    |                      |
| Liver  | 83                   |
| Lung   | 45                   |
| Peritoneum   | 18                   |
| Bone   | 4                    |
| Other  | 21                   |
| <b>Time span between molecular analysis on FFPE and liquid biopsy – days</b> |                      |
| Median   | 43                   |
| Range  | -561 to 2600         |